Eastern Pulmonary Conference 2016

Palm Beach, FL US
September 8, 2016 to September 11, 2016

The purpose of the Eastern Pulmonary Conference (EPC) is to plan and organize CME meetings on clinical topics in Pulmonary Medicine.  EPC blends the interactivity characteristic of small regional conferences together with the cutting edge science characteristic of large national meetings.  The educational goal is to share clinically relevant information which improves the diagnostic accuracy and the effectiveness of treatments with practitioners who treat pulmonary diseases.  

Target Audience

  • Practicing pulmonologists
  • Fellows in pulmonary training programs
  • Primary care physicians
  • Allied Health professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:

 ·        Discuss the basics of stem cell biology, how stem cells are harvested and what emerging clinical uses are currently being studied, including the treatment of idiopathic pulmonary fibrosis

·        Outline and apply the current guidelines for the diagnosis and treatment of outpatient community acquired pneumonia and severe pneumonia that requires hospitalization or is acquired in the hospital

·        Describe the use of biomarkers and current and future treatment options for asthma and COPD, the approach to clinical exacerbations of COPD, and the causes and clinical consequences of corticosteroid resistance

·        Discuss the current molecular approaches to the diagnosis of lung cancers and how novel treatments are applied to these cancers and how the clinician approaches a solitary pulmonary nodule to rule out cancer

·        Explain the clinical presentations, treatments and outcomes of two major non-infectious pneumonias: hypersensitivity pneumonitis and chronic organizing pneumonia

·        Outline the advances and state of the art practice of endobronchial ultrasound-guided transbronchial needle aspiration

·        Discuss the epidemiology, burden of illness and pathophysiology of pulmonary hypertension due to chronic lung disease and the use of newer anticoagulants to treat pulmonary embolic disease

·        Explain the recent advances in understanding the pathogenesis of interstitial lung diseases and the advances on treatment in idiopathic pulmonary fibrosis

·        Outline the need for immunizations for the pulmonary patient and consequences of poor adherence

·        Apply current evidence-based practices to the treatment of critically ill patients with ARDS

·        Apply principles regarding tissue hypoxia to the clinical practice including guidelines for air travel for the pulmonary patient

Additional information

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Mary Beth Beasley, MD - Speaker

Genentech: Consultant

Sidney Braman, MD – Planner, Moderator, Speaker

AstraZeneca:  Consultant, Speaker

Boehringer Ingelheim:  Consultant

Genentech:  Speaker

Sunovion: Consultant

William Corrao, MD – Moderator, Speaker

Boehringer Ingelheim:  Speaker, Honorarium

GlaxoSmithKline: Consultant

Steven Feinsilver, MD – Speaker

UpToDate:  Honorarium

Best Doctors:  Consultant


Marilyn Glassberg, MD – Speaker

Boehringer Ingelheim:  Consultant

Genentech: Consultant, Research Grant

Nicola Hanania, MD – Speaker

AstraZeneca: Consultant, Honorarium, Research Grant

Boehringer Ingelheim: Consultant, Honorarium, Research Grant

Chiesi: Research Grant

GlaxoSmithKline: Consultant, Honorarium, Research Grant

Mylan: Consultant, Honorarium, Research Grant

Roche: Consultant, Honorarium, Research Grant

Sunovion: Consultant, Research Grant

James Klinger, MD – Speaker

Actelion: Research Grant

Bayer: Consultant, Research Grant

Gilead: Research Grant

Ikaria: Research Grant

Lung RX: Research Grant

NIH: Research Grant

Pulmonary Hypertension Assoc.: Speaker, Honorarium

United Therapeutics: Consultant, Research Grant

Neil MacIntyre, MD – Speaker

Breathe Tech: Consultant

Inspirx Pharm: Consultant

Ventec: Consultant

Michael Neiderman, MD – Speaker

Bayer: Consultant, Research Grant

Cempra: Consultant

Merck: Consultant, Research Grant

Pfizer: Consultant, Honorarium

Rey Panettieri Jr., MD – Planner, Moderator, Speaker

AstraZeneca:  Consultant, Speaker, Research Grant

Genentech:  Speaker

Knopp:  Consultant

Med Immune:  Consultant, Research Grant

Novartis:  Consultant, Speaker

Regeneron:  Consultant, Research Grant

Sanofi:  Speaker, Research Grant

Teva: Speaker, Research Grant

Patricia Rivera, MD – Speaker

Boehringer Ingelheim: Consultant

Veracyte: Consultant

Russell Settipane, MD – Planner, Moderator, Speaker, Reviewer

AstraZeneca: Consultant, Speaker

Circassia: Research Grant

Genentech: Speaker, Research Grant

Greer/Stallergenes: Speaker

Meda: Speaker

Merck: Consultant, Speaker, Research Grant

Mylan: Speaker, Research Grant

Novartis: Research Grant

OceanSide Publications: Employee, Stockholder

Oriel Therapeutics: Research Grant

Teva:  Consultant, Speaker

Momen Wahidi, MD – Speaker

Boston Scientific: Consultant, Honorarium

Olympus: Consultant, Honorarium

Ginny Loiselle – Coordinator

Nothing to disclose

Course summary
Available credit: 
  • 14.50 AMA PRA Category 1 Credit™
  • 14.50 Attendance
Course opens: 
Course expires: 
Event starts: 
09/08/2016 - 4:30pm CDT
Event ends: 
09/11/2016 - 10:30am CDT
1 S. County Road
Palm Beach, FL 33480
United States

Available Credit

  • 14.50 AMA PRA Category 1 Credit™
  • 14.50 Attendance
Please login or create an account to take this course.